Regeneron Pharmaceuticals (MIC:REGN-RM) 1-Year Share Buyback Ratio : 1.80% (As of Mar. 2025 )

View and export this data going back to 2021. Start your Free Trial

What is Regeneron Pharmaceuticals 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Regeneron Pharmaceuticals's current 1-Year Share Buyback Ratio was 1.80%.

MIC:REGN-RM's 1-Year Share Buyback Ratio is ranked better than
96.68% of 1173 companies
in the Biotechnology industry
Industry Median: -11.2 vs MIC:REGN-RM: 1.80

Competitive Comparison of Regeneron Pharmaceuticals's 1-Year Share Buyback Ratio

For the Biotechnology subindustry, Regeneron Pharmaceuticals's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regeneron Pharmaceuticals's 1-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Regeneron Pharmaceuticals 1-Year Share Buyback Ratio Calculation

Regeneron Pharmaceuticals's 1-Year Share Buyback Ratio for the quarter that ended in Mar. 2025 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Mar. 2024 )	-	Shares Outstanding (EOP) (Mar. 2025 ))	/	Shares Outstanding (EOP) (Mar. 2024 )
	=	(110.186	-	108.217)	/	110.186
	=	1.8%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals (MIC:REGN-RM) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Regeneron Pharmaceuticals 1-Year Share Buyback Ratio Related Terms

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIC:REGN-RM) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 1REGN:Italy 0R2M:UK RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines